Publications by authors named "W A Macdonald"
Objectives: Prostate cancer (PCa) is a leading cause of cancer death in men worldwide. Approximately 30% of castrate-resistant PCa becomes refractory to therapy due to neuroendocrine differentiation (NED) that is present in <1% of de-novo tumors. First-in-class imipridone ONC201/TIC10 therapy has shown clinical activity against midline gliomas, neuroendocrine tumors, and PCa.
View Article and Find Full Text PDFArticle Synopsis
- Two cases of thyroid hemangioma were observed in a 62-year-old man and an 18-year-old woman, showing characteristics like mobile nodules and specific vascular indicators under microscopic examination.
- A review of existing literature found 53 cases of intrathyroidal hemangiomas, mostly in the right thyroid lobe, primarily showing features of cavernous hemangiomas, with favorable prognosis and surgical resection deemed curative due to diagnostic challenges.
Article Synopsis
- - The study investigates how T helper 2 (T2) cells, involved in allergic reactions, differentiate in barrier tissues, focusing on house dust mite-specific T cells in mice.
- - Key to T2 cell differentiation and migration is the early expression of a protein called Blimp-1, with its absence hindering T2 cell development in the lungs.
- - The findings highlight the importance of IL-2 signaling and the local environment in lymph nodes, which support the initial formation of T2 cells by promoting Blimp-1 and GATA3, crucial for allergic asthma development.
Article Synopsis
- The study investigates the association between CYP11B2 staining patterns in adrenal tissues and patient outcomes after adrenal surgery in individuals with unilateral primary aldosteronism.
- A total of 43 patients were reviewed, identifying five distinct CYP11B2 staining patterns, with most cases showing a single adenoma, but also instances of additional staining in nonadenomatous tissues.
- While the majority of patients achieved biochemical cures, the study found no correlation between CYP11B2 staining patterns and clinical outcomes or demographic factors, highlighting the need for further research to understand these relationships.
Article Synopsis
- Lutetium-177 [Lu]Lu-PSMA-617 is being studied for its effectiveness in improving survival and quality of life for patients with metastatic castration-resistant prostate cancer, but its benefits for hormone-sensitive prostate cancer are still unclear.
- The UpFrontPSMA trial involved patients with high-volume metastatic hormone-sensitive prostate cancer, who were randomly assigned to receive either [Lu]Lu-PSMA-617 followed by docetaxel or docetaxel alone as standard care.
- The primary goal of the trial was to determine if patients treated with [Lu]Lu-PSMA-617 could achieve undetectable levels of prostate-specific antigen (PSA) after 48 weeks.